NextFin News - Regeneron Pharmaceuticals has reached a landmark agreement with U.S. President Trump to lower drug prices for American consumers, headlined by a commitment to provide its newly approved gene therapy for hearing loss entirely free of charge to eligible patients. The deal, announced Thursday at the White House, marks a significant escalation in the administration’s "most favored nation" pricing strategy, which seeks to align domestic pharmaceutical costs with the lowest prices paid in other developed economies.
The centerpiece of the arrangement is Otarmeni, a breakthrough gene therapy that received Food and Drug Administration approval just hours before the deal was finalized. The treatment targets an ultra-rare genetic mutation that causes profound deafness by preventing the production of a critical protein in the inner ear. While Piper Sandler analysts previously estimated the therapy could generate peak annual sales of $130 million, Regeneron’s decision to waive costs for eligible U.S. patients effectively transforms the product into a high-profile loss leader in exchange for broader regulatory and trade concessions.
In return for these pricing guarantees, the White House has granted Regeneron a three-year exemption from pharmaceutical tariffs. This includes a waiver from U.S. President Trump’s proposed 100% levies on certain imported medical products, a policy designed to force domestic manufacturing and price reductions. The deal follows a pattern established by other major drugmakers who have traded margin on specific products for protection against the administration’s aggressive trade posture. Shares of Regeneron (REGN) responded positively to the news, trading at $759.03, up approximately 2.5% during Thursday’s session as investors weighed the cost of the concessions against the benefit of tariff immunity.
The "most favored nation" model remains a point of contention within the healthcare sector. While the administration frames these deals as essential victories for affordability, some industry analysts caution that the long-term impact on research and development remains unproven. The specific focus on Otarmeni—a therapy for an "ultra-rare" condition—suggests that the administration is targeting high-cost, low-volume breakthroughs to set a precedent for future negotiations. For Regeneron, the trade-off secures its broader portfolio from the volatility of the ongoing trade disputes, even as it sacrifices the immediate revenue potential of its latest scientific achievement.
The agreement also includes provisions for Regeneron to list certain existing medications on TrumpRx.gov, a government-backed platform intended to offer discounted drugs directly to the public. This integration into the administration’s preferred distribution channel further cements the shift toward a more interventionist federal role in the pharmaceutical market. As more companies enter similar pacts, the traditional pricing power of the biotech industry faces its most significant challenge in decades, replaced by a system of bilateral deals negotiated directly with the Oval Office.
Explore more exclusive insights at nextfin.ai.
